NTLA Intellia Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: biotechnology firm developing CRISPR-based in vivo genome editing therapies targeting severe diseases
• • New emphasis on Phase 3 products lonvo-z and nex-z for hereditary angioedema and transthyretin amyloidosis, with commercial launch preparation for lonvo-z in H1 2027
• • Strategic focus shifted towards advancing first-in-class systemic CRISPR therapies with single IV infusions in outpatient settings
• • Employee count increased with shares issued to 116.3M from 102.0M year-over-year, net loss reduced to $412.7M from $519.0M in 2024
• • Collaboration revenue grew to $67.7M from $57.9M, signaling stronger partner-based funding streams in 2025

Risk Factors

• • Regulatory risk: potential impact of SEC scrutiny on forward-looking statements disclosed in 2026 10-K
• • Geopolitical/macroeconomic risk: $117.7M common stock shares remain under the amended 2022 Sale Agreement with Jefferies exposure to market volatility
• • Operational risk: $195.1M committed lease payments starting mid-2026 for new Cambridge office/lab space could pressure cash flow
• • Competitive risk: reliance on Regeneron collaboration contributing $23.7M in cost reimbursements subject to partnership risks
• • Financial risk: $394.7M net cash used in operating activities in 2025, with runway into H2 2027 excluding milestones or new capital raises

Management Discussion & Analysis

• • No revenue or profitability data provided for fiscal year 2026
• • No segment performance or cash flow details disclosed
• • No capital allocation information such as buybacks, dividends, or capex mentioned
• • Forward-looking statements referenced but no specific management outlook or guidance included

What are the latest NTLA SEC filings in 2026?

Intellia Therapeutics, Inc. (NTLA) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 11, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did NTLA file its most recent 10-K annual report?

Intellia Therapeutics, Inc. (NTLA) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view NTLA 10-Q quarterly reports?

Intellia Therapeutics, Inc. (NTLA)'s most recent 10-Q quarterly report was filed on May 11, 2026. SignalX displays every NTLA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has NTLA filed recently?

Intellia Therapeutics, Inc. (NTLA)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find NTLA insider trading activity (Form 4)?

SignalX aggregates every NTLA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does NTLA file with the SEC?

Intellia Therapeutics, Inc. (NTLA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new NTLA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Intellia Therapeutics, Inc. (NTLA).

What is NTLA's SEC CIK number?

Intellia Therapeutics, Inc. (NTLA)'s SEC CIK (Central Index Key) number is 1652130. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1652130 to look up all NTLA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find NTLA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Intellia Therapeutics, Inc. (NTLA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.